{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT04590521: Phase 4 Interventional Completed HPV Infection
(2022)
Source URL:
First approved in 2017
Source:
BLA125614
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2010
Source:
21 CFR 333D
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M005
(2023)
Source URL:
First approved in 1968
Source:
NDA204426
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2020)
Source:
BLA761145
(2020)
Source URL:
First approved in 2015
Source:
BLA761036
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2025)
Source:
BLA761404
(2025)
Source URL:
First approved in 2010
Source:
BLA125320
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2008)
Source:
BLA125249
(2008)
Source URL:
First approved in 2008
Source:
BLA125249
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
BLA761216
(2021)
Source URL:
First approved in 2002
Source:
BLA125057
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2010)
First approved in 1998
Source:
BLA103980
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2018)
Source:
BLA761080
(2018)
Source URL:
First approved in 1991
Source:
BLA103353
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03704766: Not Applicable Interventional Recruiting Joint Infection
(2016)
Source URL:
Class:
PROTEIN
